Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) EBT (2016 - 2025)

ImmunityBio (IBRX) has disclosed EBT for 12 consecutive years, with -$62.1 million as the latest value for Q4 2025.

  • Quarterly EBT fell 4.92% to -$62.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$351.6 million through Dec 2025, up 15.0% year-over-year, with the annual reading at -$351.6 million for FY2025, 15.0% up from the prior year.
  • EBT for Q4 2025 was -$62.1 million at ImmunityBio, up from -$67.3 million in the prior quarter.
  • The five-year high for EBT was -$59.2 million in Q4 2024, with the low at -$233.5 million in Q4 2023.
  • Average EBT over 5 years is -$105.8 million, with a median of -$95.2 million recorded in 2022.
  • The sharpest move saw EBT plummeted 115.58% in 2023, then soared 74.65% in 2024.
  • Over 5 years, EBT stood at -$91.6 million in 2021, then dropped by 18.28% to -$108.3 million in 2022, then tumbled by 115.58% to -$233.5 million in 2023, then skyrocketed by 74.65% to -$59.2 million in 2024, then fell by 4.92% to -$62.1 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$62.1 million, -$67.3 million, and -$92.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.